New antibiotic studied in kids: first step toward better infection treatment

NCT ID NCT05217537

Completed Knowledge-focused Sponsor: Paratek Pharmaceuticals Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a single dose of the antibiotic omadacycline (Nuzyra) in 23 children aged 8 to 17 who were hospitalized with bacterial infections. Researchers measured how the drug moved through the body and checked for side effects. The goal was to gather safety and dosing information, not to treat the infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omadacycline (Nuzyra)
What this could lead to: If successful, this could help determine the right dose of omadacycline for children with bacterial infections.
What could go wrong: This is a very early, small study (23 children) that only looked at a single dose. It does not prove the drug works or is safe for long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BACTERIAL INFECTIONS

Contacts and locations

Locations

Site 105

Chicago, Illinois, 60611, United States
Site 106

Cleveland, Ohio, 60611, United States
Site 107

Orange, California, 92868, United States
Site 108

Houston, Texas, 77030, United States
Site 109

Little Rock, Arkansas, 72202, United States
Site 111

Greenville, North Carolina, 27858, United States
Site 112

Long Beach, California, 90806, United States
Site 113

Philadelphia, Pennsylvania, 19104, United States
Site 114

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.